

Univ. Prof. Dr. med. Johann Bauersachs

Department of Cardiology and Angiology

Hannover Medical School

Carl-Neuberg-Str. 1

D-30625 Hannover

Tel. +49-511-532 3481

Fax +49-511-532 5412

E-Mail: bauersachs.johann@mh-hannover.deTwitter: [@JBauersachsMD](https://twitter.com/JBauersachsMD)<http://www.mhh-kardiologie.de/>[https://en.wikipedia.org/wiki/Johann Bauersachs](https://en.wikipedia.org/wiki/Johann_Bauersachs)**Profile**

Professor Bauersachs acts as Head of the Department of Cardiology and Angiology at Hannover Medical School (MHH). He studied Medicine at the University of Freiburg. After training as Clinical and Research Fellow at the Universities of Frankfurt and Heidelberg/ Mannheim, in 1999 he moved to the University Hospital Wuerzburg where he became Consultant and Lecturer in Internal Medicine and Cardiology, and was Associate Professor in the Department of Medicine from 2008 to 2010. Since 2010 Johann Bauersachs has been a Full Professor and Director of the MHH-Department of Cardiology and Angiology.

Professor Bauersachs is Fellow of the American Heart Association, Fellow of the European Society of Cardiology (ESC), Fellow of the Heart Failure Association (HFA) of the ESC, Chair of the HFA Committee on Peripartum Cardiomyopathies (PPCM), and Co-Chair of the worldwide EORP Registry on PPCM. He is Speaker of the Clinical Research Group (KFO) 311 “(Pre-) terminal heart and lung failure - mechanical unloading and repair” funded by the Deutsche Forschungsgemeinschaft (DFG). Professor Bauersachs is Board member of the German Cardiac Society (DGK).

Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodelling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of PPCM, in aldosterone and mineralocorticoid receptor-mediated mechanisms, and in the role of non-coding RNAs.

Professor Bauersachs is Principal Investigator of HF-REVERT (Phase 2 study to assess the microRNA inhibitor CDR132L in patients after myocardial infarction). He is Study Chair of the DIGIT-HF study investigating the effect of Digitoxin on morbidity/mortality in patients with advanced heart failure, and is extensively involved in many other clinical trials.

Metrics (web of science)

Publications	1020
H index	101

Education/Academic Appointments

13.12.1993	Thesis (M.D.) at the University of Freiburg, Department of Physiology
12/1993-07/1995	Residency in Internal Medicine, University Hospital Frankfurt
08/1995-10/1996	Postdoctoral/Research Associate, Physiology, University of Frankfurt
11/1996-07/1999	Residency and Fellowship in Internal Medicine, University Hospital Mannheim
08/1999-02/2003	Residency and Fellowship in Internal Medicine and Cardiology, Department of Medicine, University of Würzburg
08/2000	Board Certification „Internal Medicine“
01/2002	Board Certification „Cardiology“
11-12/2001	Habilitation, Member of the Faculty, senior lecturer, Dept. of Medicine, Division of Cardiology, University of Würzburg
03/2003-09/2010	Consultant Cardiology/Intensive Care, University Hospital Würzburg
12/2008	Board Certification „Intensive Care“
01/2008-09/2010	Associate Professor, Dept. of Medicine I, University Hospital Würzburg
01/2010	Call for W3-Professorship Cardiology/Angiology, University Hospital Giessen
since 10/2010	Full Professor and Director, Department of Cardiology and Angiology, MHH
since 04/2020	Chair of the Center of Internal Medicine, Hannover Medical School

Current and Previous Professional Activities

Speaker of the Clinical Research Group (KFO) 311, “(Pre-)terminal heart and lung failure – mechanical unloading and repair” (www.mhh.de/kfo311/), funded by the Deutsche Forschungsgemeinschaft/DFG
Member of the DFG Cardiovascular Review Board (Fachkollegium Medizin) 2012-2020, Chair 2016-2020

European Society of Cardiology (ESC), Fellow, Heart Failure Association (HFA) of the ESC, Fellow
Chair of the HFA Study Group Peripartum Cardiomyopathy 2014-22,
Chair of the HFA Committee on Peripartum Cardiomyopathies 2022-24
HFA Board member 2013-2020, Chair of the HFA Clinical Section 2018-20
Member of the ESC Congress Programme Committee 2013-18, and 2020-22
Member of the ESC Communication Committee 2020-22
Chair of the ESC Working Group on Myocardial Function 2012-2014
Member of the ESC Guidelines Task Forces “Management of cardiovascular diseases during pregnancy 2018”, “Management of acute coronary syndromes in patients presenting without ST-segment elevation 2020”, and “ESC/EACTS Guidelines for the management of valvular heart disease 2021”

German Cardiac Society (DGK), Board Member 2017-23

Member of the Committee on Clinical Cardiovascular Medicine 2017-21, Chair 2019-21

Congress President “DGK Herztage 2018”; Member of the DGK Program Committee 2014-2018

Member of the Scientific Advisory Board of the German Foundation for Heart Research since 2022

ESAC Germany (European Section of Aldosterone Council) Association; President

DIGIT-HF Study (<http://digit-hf.de/>): “DIGitalis to Improve ouTcomes in patients with advanced chronic Heart Failure”, funded by BMBF (Bundesministerium für Bildung und Forschung), Study Chair

Cardior Pharm. (www.cardior.de/), Member Advisory Board 2017-21, Scientific Advisory Board 2022-;

Principal investigator of HF-REVERT: “Phase 2 study to assess efficacy and safety of the miRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction ($\leq 45\%$) after myocardial infarction”

Awards and Prizes

2001 Oskar-Lapp-Award, German Cardiac Society

2004 Albert-Fraenkel-Award, German Cardiac Society

2006 Parmley-Award, American College of Cardiology

2012 Bernard and Joan Marshall Distinguished Investigator Award, British Soc. for Cardiovasc. Research

2016 Honorary Member of the Korean Society of Cardiology

2018 Paul-Morawitz-Award, German Cardiac Society

2019 Honorary Member of the Rumanian Society of Cardiology

2021 Silver Badge of Honour, German Cardiac Society

Patents

PCT/EP2007/008772: microRNA (miRNA) for the diagnosis and treatment of heart diseases

PCT/EP2009/051986: microRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes

Major Research Interests

Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodelling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of peripartum cardiomyopathy, in aldosterone and mineralocorticoid receptor-mediated mechanisms and the role of non-coding RNAs.

Deputy Editor

European Heart Journal

Associate Editor

Cardiovascular Research

Editorial Consultant

JACC Heart Failure

Editorial Board Member

Basic Research in Cardiology, Clinical Research in Cardiology, ESC Heart Failure, Herz – Cardiovascular Diseases

Reviewer for

Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, INSERM und ANR-Frankreich, Circulation, Circulation Research, Hypertension, JACC, Cardiovascular Research, European Journal of Heart Failure, etc

Selected Publications (of more than 700 listed in pubmed)

Bauersachs J, Soltani S. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango. *Eur Heart J* 2023; doi: 10.1093/eurheartj/ehad540

*Jackson AM, ***Bauersachs J**, Petrie MC, van der Meer P, ..., Maggioni AP, Briton O, Sliwa K; EurObservational Research Programme in conjunction with the HFA of the ESC Study Group on Peripartum Cardiomyopathy. Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM Registry. *Eur J Heart Fail*; doi: 10.1002/ejhf.3055

Greene SJ, **Bauersachs J**, Brugts JJ, Ezekowitz JA, Filippatos G, Gustafsson F, Lam CSP, Lund LH, Mentz RJ, Pieske B, Ponikowski P, Senni M, Skopicki N, Voors AA, Zannad F, Zieroth S, Butler J. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3. *J Am Coll Cardiol*. 2023;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057.

Diekmann J, Neuser J, Röhrich M, Derlin T, Zwadlo C, Koenig T, Weiberg D, Jäckle F, Kempf T, Ross TL, Tillmanns J, Thackeray JT, Widder J, Haberkorn U, **Bauersachs J**, Bengel FM. Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study. *J Nucl Med*. 2023;64(8):1279-1286. doi: 10.2967/jnumed.122.265147.

Mullens W, Schulze PC, Westphal J, Bogoviku J, **Bauersachs J**. Great Debate: In patients with decompensated heart failure Acetazolamide in addition to loop diuretics is the first choice. *Eur Heart J*. 2023;44(24):2159-2169. doi: 10.1093/eurheartj/ehad266.

Bavendiek U, Großhennig A, ..., Störk S, Koch A, **Bauersachs J**. Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial. *Clin Res Cardiol* 2023; doi: 10.1007/s00392-023-02199-z.

van Veldhuisen D, **Bauersachs J**. Digitalis in Heart Failure: declining use and ongoing outcome trials. *Eur Heart J* 2023, doi: 10.1093/eurheartj/ehad185

Greene SJ, **Bauersachs J**, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, Ponikowski P, Voors AA, Zannad F, Zieroth S, Butler J. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2023; 81:413-424. doi: 10.1016/j.jacc.2022.11.023

de Boer RA, **Bauersachs J**. The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies. *Eur Heart J*. 2023 Jan 2;ehac781. doi: 10.1093/eurheartj/ehac781.

Bauersachs J, Olsson KM. Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development? *Eur Heart J*. 2022 Aug 1;ehac387. doi: 10.1093/eurheartj/ehac387.

Bauersachs J, Koenig T. Peripartum cardiomyopathy - a global challenge. *Eur J Heart Fail*. 2022 Jul 23. doi: 10.1002/ejhf.2636.

Frantz S, Hundertmark M, Schulz-Menger J, Bengel F, **Bauersachs J**. Left ventricular remodelling post myocardial infarction: pathophysiology, imaging and novel therapies. *Eur Heart J*. 2022, ehac223. doi: 10.1093/eurheartj/ehac223.

Reboll MR, Klede S, Taft MH, Cai CL, Field LJ, ..., van den Heuvel J, Pich A, **Bauersachs J**, Wu X, Zheng L, Wang Y, Korf-Klingebiel M, Polten F, Wollert KC. Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. *Science* 2022;376(6599):1343-1347. doi: 10.1126/science.abn3027.

Chioncel O, Adamo M, **Bauersachs J**. Risk Stratification in Cardiogenic Shock: from clinical utility to improving outcomes. *Eur J Heart Fail*. 2022. doi: 10.1002/ejhf.2465.

Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. *Eur Heart J*. 2022; 43:367-376. doi: 10.1093/eurheartj/ehab887

Szaroszyk M, Kattih B, Martin-Garrido A, ..., Wollert KC, Fielitz J, von Haehling S, Kuhn M, **Bauersachs J**, Heineke J. Skeletal muscle derived Musclin protects the heart during pathological overload. *Nature Communications* 2022, 13:149. doi: 10.1038/s41467-021-27634-5

Bauersachs J, López-Andrés N. Mineralocorticoid receptor in cardiovascular diseases - Clinical trials and mechanistic insights. *Br J Pharmacol*. 2021 Oct 13. doi: 10.1111/bph.15708.

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, **Bauersachs J**, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, ..., Tribouilloy C, Wojakowski W. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2021 doi: 10.1093/eurheartj/ehab395.

Fraccarollo D, Neuser J, Möller J, Riehle C, Galuppo P, **Bauersachs J**. Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. *Elife*. 2021; 10:e66808. doi: 10.7554/eLife.66808.

Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, **Bauersachs J**. The struggle towards a universal definition of heart failure-how to proceed? *Eur Heart J*. 2021;42:2331-2343. doi: 10.1093/eurheartj/ehab082

Bauersachs J. Heart failure drug therapy – the fantastic four. *Eur Heart J*. 2021; 42:681-683. doi: 10.1093/eurheartj/ehaa1012.

Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, Schäfer A, Ross TL, **Bauersachs J**, Bengel FM. Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region After Acute Myocardial Infarction. *J Am Coll Cardiol*. 2021;77:1835-1837. doi: 10.1016/j.jacc.2021.02.019.

Bueno H, Moura B, Lancellotti P, **Bauersachs J**. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. *Eur Heart J*. 2021 Jan 3;ehaa1061. doi: 10.1093/eurheartj/ehaa1061.

Sliwa K, van der Meer P, Petrie MC, ..., Rosano G, Seferovic PM, **Bauersachs J**. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the HFA of the ESC Study Group on Peripartum Cardiomyopathy. *Eur J Heart Fail*. 2021 Apr;23(4):527-540. doi: 10.1002/ejhf.2133.

Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, **Bauersachs J**, Solomon SD, Thum T. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. *Eur Heart J*. 2020; doi: 10.1093/eurheartj/ehaa898

Collet JP, Thiele H, Barbato E, Barthélémy O, **Bauersachs J**, Bhatt DL, Dendale P, ..., Rutten FH, Sibbing D, Siontis GCM. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2020; doi: 10.1093/eurheartj/ehaa575.

Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, ..., Ponikowski P, Van Veldhuisen DJ, McMurray J, **Bauersachs J**. Clinical presentation, management and 6-month outcomes in women with peripartum cardiomyopathy, an ESC EORP registry. *Eur Heart J* 2020, doi: 10.1093/eurheartj/ehaa455

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, ..., Neudorf U, Pfister R, von Haehling S, Lehmann LH, **Bauersachs J**. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. *Clin Res Cardiol* 2020; doi: 10.1007/s00392-020-01636-7

Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, ..., Duncker D, Veltmann C, Hilfiker-Kleiner D, **Bauersachs J**. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. *Eur J Heart Fail*. 2019; 12:1534-1542. doi: 10.1002/ejhf.1624.

Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, ..., Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the HFA of the ESC Study Group on peripartum cardiomyopathy. *Eur J Heart Fail*. 2019. doi: 10.1002/ejhf.1493.

Fraccarollo D, Thomas S, Scholz CJ, Hilfiker-Kleiner D, Galuppo P, **Bauersachs J**. Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. *Hypertension*. 2019. 73:102-111. doi: 10.1161/HYPERTENSIONAHA.118.12162

Bavendiek U, Berliner D, Aguirre Dávila L, ..., v. d. Leyen H, Schröder C, Veltmann C, Störk S, Böhm M, Koch A, **Bauersachs J**. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. *Eur J Heart Fail*, 2019 21(5):676-684. doi: 10.1002/ejhf.1452

Riehle C, **Bauersachs J**. Small animal models of heart failure. *Cardiovasc Res* 2019;115(13):1838-1849. doi: 10.1093/cvr/cvz161

Regitz-Zagrosek V, Roos-Hesselink JW, **Bauersachs J**, Blomström-Lundqvist C, Cifková R, De Bonis M, Iung B,, Swan L, Warnes CA. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J* 2018, 39: 3165-3241.

Koehler F, Koehler K, Deckwart O, ... Schulze PC, **Bauersachs J**, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. *Lancet*. 2018 pii: S0140-6736(18)31880-4. doi: 10.1016/S0140-6736(18)31880-4.

Riehle C, **Bauersachs J**. Of mice and men: models and mechanisms of diabetic cardiomyopathy. *Basic Res Cardiol*. 2018;114:2. doi: 10.1007/s00395-018-0711-0

Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J,, Podewski E, Böhm M, Sliwa K, **Bauersachs J** (2017). Bromocriptine for the Treatment of Peripartum Cardiomyopathy: A Multicenter Randomized Study. *Eur Heart J* 38, 2671-2679.

Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C,, Dickstein K, Schultheiss HP, Ladage D, Greulich S, **Bauersachs J** (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. *Eur Heart J*, doi: 10.1093/eurheartj/ehx188

Bavendiek U, Aguirre Davila L, Koch A, **Bauersachs J** (2017). Assumption versus evidence – the case of digoxin in atrial fibrillation and heart failure. *Eur Heart J*, pii: ehw577. doi: 10.1093/eurheartj/ehw577

Bauersachs J, Arrigo M, Denise Hilfiker-Kleiner DF,, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K (2016). Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the HFA of the ESC Study Group on peripartum cardiomyopathy. *Eur J Heart Fail* 18, 1096-105

Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. *Hypertension* 2015; 65, 257-263.

Hilfiker-Kleiner D, Haghikia A, Nonhoff J, **Bauersachs J** (2015). Peripartum cardiomyopathy: current management and future perspectives. *Eur Heart J*, DOI: 10.1093/eurheartj/ehv009

Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, **Bauersachs J**. (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. *Circulation* 123, 400-408

Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. *Circ Res* 109, 334-47

Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, **Bauersachs J** (2011). Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. *Eur Heart J* 32, 1275-86

Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, **Bauersachs J***, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 456, 980-984 *joint senior authors

Fraccarollo D, Widder JD, Galuppo P, Thum T, Hoffmann M, Ruetten H, Ertl G, **Bauersachs J** (2008). Improvement of left ventricular remodelling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. *Circulation* 118, 818-82

Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, **Bauersachs J** (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. *Circulation* 116, 258-267